SGLT2 inhibitors and acute kidney injury
Nephrology Dialysis Transplantation · 30.01.2026 · 41 (2) · 243-254
DOI: 10.1093/ndt/gfaf132 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 30.07.2025. Verfasst von Yuki Nakao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Renal Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Acute Kidney Injury, Kidney, Sodium-Glucose Transporter 2 Inhibitors, Protective Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science, NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are glucose-lowering agents that inhibit glucose reabsorption by the proximal tubules of the kidney. Since the introduction of the first SGLT2i in 2012, dapagliflozin, canagliflozin and empagliflozin have been developed and have been rapidly integrated into clinical medicine, initially to manage type 2 diabetes. Over a short period of time, however, it has become apparent that SGLT2i not only reduce blood glucose but also provides long-term protective effects to the kidneys and heart. In this review, we present physiological data on what is known about SGLT2i effects on the kidney and the ever-expanding clinical data relating to the effects of SGLT2i on the occurrence of acute kidney injury (AKI), and integrate what is known about molecular mechanisms with clinical experience. We conclude that SGLT2i may reduce the risks for AKI in humans. We speculate on mechanisms by which SGLT2 inhibitors may protect against AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Renal Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, MA, USA.
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Förderung
- Japan Society for the Promotion of Science
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Nakao, Y., Mori, M., Mori, Y., & Bonventre, J. V. (2026). SGLT2 inhibitors and acute kidney injury. Nephrology Dialysis Transplantation, 41(2), 243-254. https://doi.org/10.1093/ndt/gfaf132
Vancouver
Nakao Y, Mori M, Mori Y, Bonventre JV. SGLT2 inhibitors and acute kidney injury. Nephrology Dialysis Transplantation. 2026;41(2):243-254. doi:10.1093/ndt/gfaf132
BibTeX
@article{Nakao2026,
author = {Nakao, Yuki and Mori, Makiko and Mori, Yutaro and Bonventre, Joseph V},
title = {SGLT2 inhibitors and acute kidney injury},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {2},
pages = {243--254},
doi = {10.1093/ndt/gfaf132}
}
EUVIMED